My illness previously dictated how I planned my days, years and entire sense of possibility – pregnancy has disrupted that ...

The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has ...

The iBox Scoring System is a novel composite biomarker endpoint predictive of long-term graft survival after kidney ...

PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy IND clearance follows the granting of European Medicine Agency (EMA ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Game Changers in Nephrology' was the theme of the 62nd European Renal Association (ERA) Congress, held in Vienna, ...

Witnessing her son's ongoing pain and deteriorating health, his mother took the brave decision to donate one of her kidneys.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Patrick Maxwell, Regius Professor of Physic and Head of the School of Clinical Medicine at the University of Cambridge, UK ...